- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
The Company is into manufacturing of agrochemical active ingredients (technical), bulk and formulations, intermediate products and it sells its products in India as well as exports them to approximately 24 countries.Astec also has undertaken a number of custom synthesis projects, for its clients in Europe, Japan and the US. It is present only in business to business sale (B2B).
Astec LifeSciences has set record dates for the maturity payment of its Commercial Papers (CPs). Investors holding CPs with ISINs INE563J14DO8, INE563J14DP5, and INE563J14DQ3 will receive their Rs. 25 Cr maturity amounts. The record dates are September 18, 2026, September 16, 2026, and October 12, 2026, respectively, for payments due...
Astec LifeSciences reported improved FY26 results: Total income reached ₹453.22 Cr, gross margin rose to 33.4%, and losses narrowed. Domestic sales surged 40.6%. A ₹249.35 Cr rights issue was completed. Focus continues on bolstering CDMO & R&D. A prior year regulatory penalty of ₹2.60 lakh each was paid to NSE/BSE.